GemPharmatech and Humlab partner on global distribution of humanized mouse models

Summary

GemPharmatech is a leading Chinese genetically engineered mouse company and says it holds more than 30,000 knockout, conditional knockout, humanized and immunodeficient strains; Humlab is a Singapore-based developer of humanized mice. The agreement covers both companies' existing and newly developed humanized strains, including aging models, autoimmune and inflammatory models such as IBD and systemic lupus erythematosus, MASH metabolic models, oncology and infection models, and a new humanized-liver mouse. With the FDA pushing to reduce animal testing, growth for animal-model companies is shifting toward more “human-like” humanized models. Humlab's statements about engraftment efficiency are the company's own; the release did not include data.

Deal terms, as disclosed

Global distribution agreement; financial terms, duration and exclusivity not disclosed.

Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.

← Newerargenx to acquire Forte for $2.2B, adding anti-CD122 antibody FB102Jul 2026Older →Avere in-licenses Hansoh's oral IL-23 drug, lists via NextCure reverse merger and raises $320MJul 2026

Related same deal type

• Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203Oct 2026
• Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to RocheSep 2026
• Haisco immunology asset goes into ARCH-founded NewCo SentiveraAug 2026
• J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026

Working on a China asset or a NewCo?

Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.

NewCo services